Tag: VIVA 2021
Avinger announces FDA clearance of Pantheris for the treatment of in-stent...
Avinger recently announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for a new clinical indication for the...
Vascular News 92 – November 2021 US Edition
In this issue:
Next generation of vascular surgeons need open and endovascular skills
Head-to-head trial shows superiority of FemoSeal over ProGlide for peripheral interventions
...
Vascular News 92 – November 2021
In this issue:
Next generation of vascular surgeons need open and endovascular skills
Head-to-head trial shows superiority of FemoSeal over ProGlide for peripheral interventions
...
PROMISE I 24-month results “validate the benefits of the LimFlow system”
LimFlow SA has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialisation system, confirming "excellent and sustained outcomes"...
Eighteen-month PRESTIGE BTK data presented at VIVA 2021
Eighteen-month results from the PRESTIGE below-the-knee (BTK) study were presented as a late-breaking clinical trial at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA). The...
Positive data for the EkoSonic endovascular system presented at VIVA 2021
Boston Scientific announced positive results for the EkoSonic endovascular system (EKOS system) during a late-breaking clinical trial presentation at Vascular Interventional Advances (VIVA) 2021...
Results from first-in-human study of Amplifi vein dilation system presented at...
Preliminary clinical results from a first-in-human study assessing the Amplifi vein dilation system (Artio Medical) were presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October...
VIVA 2021: IN.PACT Admiral DCB found to provide “high five-year freedom...
Real-world data drawn from the IN.PACT Global study looking at five-year freedom from clinically-driven target lesion revascularisation (TLR) among prespecified chronic total occlusion (CTO),...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
VIVA 2021: IVL “consistently” treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL; Shockwave Medical) performs “consistently well” across challenging peripheral vessels,...
IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...
One-year results show “superior” primary patency rate for Eluvia DES compared...
One-year results presented at Vascular Interventional Advances (VIVA) 2021 (5–7 October, Las Vegas, USA) from the EMINENT trial demonstrated the superiority of the Eluvia...
VIVA 2021: Consensus established for appropriate use of IVUS in peripheral...
A worldwide committee of 40 cross-speciality medical experts achieved the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS) in peripheral vascular disease...
